

#9KH  
4/29/03



Attorney Docket No.: 5738.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: August 8, 2001

Examiner: To be assigned

For: Novel Process

RECEIVED  
APR 11 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Advanced Organic Chemistry, Fourth Edition, 1992, J. March, page 649
2. Organic Chemistry, Fourth Edition, 1983, Morrison and Boyd, page 1273

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

04/29/2003 PHILSON 00000003 141447 09924350

01 FC:1806 180.00 CH

This information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is (*check off either one*)

☐ the statement as specified in 37 C.F.R. § 1.97(e)


**or**

☒ the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Please charge any other fees, should they be required, to Novo Nordisk® Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: April 1, 2003




Cheryl H. Agris, Reg. No. 34,086  
Outside Counsel for  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800



23650

PATENT TRADEMARK OFFICE

1624



Attorney Docket No.: 5738.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

Serial No.: 09/924,350

Group Art Unit: To be assigned

Filed: August 8, 2001

Examiner: To be assigned

Confirmation No.: 3619

For: Novel Process

RECEIVED

APR 11 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (2)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on April 1, 2003.

Dolly Kapadia  
(name of person mailing paper)

Dolly Kapadia  
(signature of person mailing paper)